In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. - Ieranò C; Righelli D; D'Alterio C; Napolitano M; Portella L; Rea G; Auletta F; Santagata S; Trotta AM; Guardascione G; Liotti F; Prevete N; et al. (Journal for immunotherapy of cancer, 2022)